TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34544660

Group type: EXPERIMENTAL
Intervention: Intensive training (written materials plus live training with coaching and active monitoring)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Minimal training (written materials only)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intensive training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Minimal training
Number of subjects: 50
Study: 33760866

Group type: EXPERIMENTAL
Intervention: HPV test (OncoE6TM Cervical Test) specific to HPV16/18 in cervical swabs
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Visual inspection with acetic acid (VIA)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: History of sexually transmitted illnesses (STIs)
Number of subjects: 337
Study: 33250384

Group type: EXPERIMENTAL
Intervention: 10 Hz repetitive TMS (rTMS) to the left DLPFC (110% resting motor threshold)
Number of subjects: 22

Group type: COMPARATOR
Intervention: 10 Hz repetitive TMS (rTMS) to the left MC (90% resting motor threshold)
Number of subjects: 22
Study: 32303894

Group type: EXPERIMENTAL
Intervention: ADAPT (14-week face-to-face group intervention)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Control group (services as usual)
Number of subjects: 145
Study: 34929030

Group type: EXPERIMENTAL
Intervention: M. tuberculosis-specific CD4+ cytokine responses during late pregnancy (third trimester)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: M. tuberculosis-specific CD8+ cytokines
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Nonspecific T-cell activation
Number of subjects: 49
Study: 33583728

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided technique
Number of subjects: 14

Group type: COMPARATOR
Intervention: Blind technique
Number of subjects: 14
Study: 34147014

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Intravenous (IV) pertuzumab and trastuzumab
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: PH FDC SC continuation
Number of subjects: 160

Group type: COMPARATOR
Intervention: Patient treatment room time
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs)
Number of subjects: 160
Study: 33225961

Group type: COMPARATOR
Intervention: Standard fortification (HMF, Nutricia)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Targeted fortification (modular components: Bebilon Bialka, Nutricia—protein; Polycal, Nutricia—carbohydrates; Calogen, Nutricia—lipids)
Number of subjects: 0
Study: 35018561

Group type: EXPERIMENTAL
Intervention: Intervention (smoking cessation coaching, nicotine replacement therapy, money management coaching, referral to financial benefits and empowerment services)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Intervention among medical center participants
Number of subjects: 410

Group type: COMPARATOR
Intervention: Control (usual care during a 6-month waiting period)
Number of subjects: 410
Study: 33430250

Group type: EXPERIMENTAL
Intervention: Morning-BRJ (8:00 HR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Morning-placebo (8:00 HR)
Number of subjects: 10
Study: 35668499

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) kits distributed by trained promotors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vouchers for free HIVST at nearby clinics distributed by control promotors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement of 6- and 12-month viral load in those living with HIV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement of PrEP adherence via urine tenofovir levels among those without HIV
Number of subjects: 0
Study: 32698860

Group type: EXPERIMENTAL
Intervention: Automated ventilation (AV) using INTELLiVENT‐ASV®
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Automated ventilation (AV)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 265
Study: 33656939

Group type: EXPERIMENTAL
Intervention: Green Dot bystander intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34135084

Group type: EXPERIMENTAL
Intervention: Mendelian randomization methods applied to investigate causal relationships of risk factors with kidney function or CKD.
Number of subjects: 0
Study: 32402496

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) applied in osteotomy sites after fixation
Number of subjects: 44

Group type: COMPARATOR
Intervention: No PRF (control group)
Number of subjects: 44
Study: 32876962

Group type: EXPERIMENTAL
Intervention: High frequent low dosage IVIg treatment (half individual dose at half the interval)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Low frequent high dosage IVIg treatment (individual IVIg dose and interval)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High frequent low dosage IVIg treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Low frequent high dosage IVIg treatment
Number of subjects: 25
Study: 32508341

Group type: EXPERIMENTAL
Intervention: Backward treadmill training (BTT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard forward treadmill training (FTT)
Number of subjects: 18
Study: 35698074

Group type: EXPERIMENTAL
Intervention: MultiPill-Exercise
Number of subjects: 320

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 320
Study: 34470492

Group type: EXPERIMENTAL
Intervention: BoNT‐A injection
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 35759320

Group type: EXPERIMENTAL
Intervention: Low-effort recruitment strategies (both mass and direct)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Direct, high-effort recruitment strategies
Number of subjects: 457

Group type: COMPARATOR
Intervention: Mass recruitment strategies
Number of subjects: 457
Study: 33019892

Group type: EXPERIMENTAL
Intervention: Pedometer-based intervention over 8 weeks
Number of subjects: 259
Study: 32820002

Group type: EXPERIMENTAL
Intervention: ICP + PbtO2 group
Number of subjects: 300

Group type: COMPARATOR
Intervention: ICP group
Number of subjects: 300
Study: 35863457

Group type: EXPERIMENTAL
Intervention: Oteseconazole (600 mg on day 1 and 450 mg on day 2)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Fluconazole (3 sequential 150-mg doses every 72 hours)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Oteseconazole (150 mg weekly for 11 weeks)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo (150 mg weekly for 11 weeks)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Oteseconazole (induction and maintenance phases)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Fluconazole (induction phase) and Placebo (maintenance phase)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Oteseconazole
Number of subjects: 219

Group type: COMPARATOR
Intervention: Fluconazole and Placebo
Number of subjects: 219
Study: 34298148

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control group (low-fat diet)
Number of subjects: 190
Study: 33245788

Group type: EXPERIMENTAL
Intervention: #Tamojunto2.0 program (12 classes supervised by the Ministry of Health)
Number of subjects: 5208

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 5208
Study: 33028408

Group type: EXPERIMENTAL
Intervention: Replacing the nail plate after nail bed repair
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discarding the nail plate after nail bed repair
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions (Replacing and Discarding)
Number of subjects: 0
Study: 35193441

Group type: EXPERIMENTAL
Intervention: Dose reduction (DR) of adalimumab
Number of subjects: 118

Group type: COMPARATOR
Intervention: Usual care (UC) for adalimumab
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Dose reduction (DR) of ustekinumab
Number of subjects: 118

Group type: COMPARATOR
Intervention: Usual care (UC) for ustekinumab
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Dose reduction (DR) of etanercept
Number of subjects: 118

Group type: COMPARATOR
Intervention: Usual care (UC) for etanercept
Number of subjects: 118
Study: 32965727

Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Hot Water Immersion (HWI)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Single Ischemic Occlusion
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Double Ischemic Occlusion
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Cold Pack Application
Number of subjects: 101
Study: 32812667

Group type: EXPERIMENTAL
Intervention: Automated exchange transfusion
Number of subjects: 83

Group type: COMPARATOR
Intervention: Manual exchange transfusion
Number of subjects: 83

Group type: COMPARATOR
Intervention: Simple transfusion
Number of subjects: 83
Study: 35945733

Group type: EXPERIMENTAL
Intervention: Thread embedding acupuncture (TEA), administered once a week for 6 weeks (total of 6 sessions) on 14 defined knee areas.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acupuncture, administered twice a week for 6 weeks (total of 12 sessions) on 9 defined acupuncture points.
Number of subjects: 40
Study: 33230077

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) bi-weekly for 6 weeks
Number of subjects: 8
Study: 32482147

Group type: EXPERIMENTAL
Intervention: Constant work rate cycle ergometry (CWRCE)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Endurance shuttle walking test (ESWT)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 35238476

Group type: EXPERIMENTAL
Intervention: Continuous intravenous ornithine phenylacetate (OP) at doses of 10, 15, or 20 g/day based on Child–Turcotte–Pugh score
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous intravenous ornithine phenylacetate (OP)
Number of subjects: 0
Study: 36418494

Group type: EXPERIMENTAL
Intervention: Real-time ultrasound as visual biofeedback
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard care group (verbal instruction, verbal reinforcement, and tactile cueing)
Number of subjects: 24
Study: 33818978

Group type: EXPERIMENTAL
Intervention: Weekly injection (more effective)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Weekly injection with decoy
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: Every-three-month injection with decoy
Number of subjects: 750
Study: 32600400

Group type: EXPERIMENTAL
Intervention: Internet-based psychodynamic treatment (IPDT)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Internet-based cognitive behavioural therapy (ICBT)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: IPDT
Number of subjects: 270

Group type: COMPARATOR
Intervention: ICBT
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: IPDT and ICBT
Number of subjects: 270
Study: 36058694

Group type: EXPERIMENTAL
Intervention: Sedated state
Number of subjects: 21
Study: 33999960

Group type: EXPERIMENTAL
Intervention: Sugar sweetened beverages (SSB, 248 kcal, 20 fluid ounces)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sugar sweetened solids (SSS, equivalent caloric intake to SSB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sugar sweetened beverages (SSB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sugar sweetened solids (SSS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both SSB and SSS
Number of subjects: 20
Study: 32589455

Group type: EXPERIMENTAL
Intervention: VR game environment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Immersive desktop game environment
Number of subjects: 25
Study: 33609762

Group type: EXPERIMENTAL
Intervention: Compression dressing alone
Number of subjects: 64

Group type: COMPARATOR
Intervention: Compression dressing followed by sandbag compression
Number of subjects: 64
Study: 36434888

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 32918131

Group type: COMPARATOR
Intervention: Ranking‐UP (WEAK) group
Number of subjects: 15
Study: 35119462

Group type: EXPERIMENTAL
Intervention: Standard FIT mailed outreach plus an automated primer message through the electronic patient portal (intervention group)
Number of subjects: 2339

Group type: COMPARATOR
Intervention: Standard FIT mailed outreach (control group)
Number of subjects: 2339
Study: 34545652

Group type: EXPERIMENTAL
Intervention: Controlled-release dinoprostone vaginal delivery system (PROPESS)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Metreurynter
Number of subjects: 117
Study: 32561673

Group type: EXPERIMENTAL
Intervention: S-ketamine (NMDAR antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35667400

Group type: EXPERIMENTAL
Intervention: Intravenous labetalol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intravenous nitroglycerine
Number of subjects: 50
Study: 33188584

Group type: EXPERIMENTAL
Intervention: 1% DCI
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 0.25% DCI
Number of subjects: 46

Group type: COMPARATOR
Intervention: 1% DCI, 0.25% DCI, vehiculum without active agent
Number of subjects: 46
Study: 34853086

Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg every 2 or 4 weeks)
Number of subjects: 230
Study: 33058553

Group type: EXPERIMENTAL
Intervention: Miglitol test formulation/sucrose coadministration
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Miglitol reference formulation/sucrose coadministration
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sucrose administration alone
Number of subjects: 48
Study: 34313598

Group type: EXPERIMENTAL
Intervention: Real-time remote auscultation using a Bluetooth-connected electronic stethoscope
Number of subjects: 20

Group type: COMPARATOR
Intervention: Classical auscultation using a traditional stethoscope
Number of subjects: 20
Study: 32867690

Group type: EXPERIMENTAL
Intervention: New prediction model (nomogram) including estimated glomerular filtration rate (eGFR), serum albumin (ALB), age, and use of intra-aortic balloon pump (IABP)
Number of subjects: 1272

Group type: EXPERIMENTAL
Intervention: New prediction model (nomogram)
Number of subjects: 1272

Group type: COMPARATOR
Intervention: Classic Mehran CA-AKI model
Number of subjects: 1272
Study: 33091687

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 89
Study: 35777008

Group type: EXPERIMENTAL
Intervention: Lactobacillus fermentum CECT5716
Number of subjects: 101

Group type: COMPARATOR
Intervention: Maltodextrin (Control)
Number of subjects: 101
Study: 34302323

Group type: EXPERIMENTAL
Intervention: Interstitial photodynamic therapy (IPDT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care (SoC) treatment
Number of subjects: 0
Study: 33037320

Group type: EXPERIMENTAL
Intervention: H4:IC31 (subunit vaccine containing Ag85B and TB10.4)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: BCG (live attenuated vaccine)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 35674488

Group type: EXPERIMENTAL
Intervention: EDS-FLU 186 μg
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: EDS-FLU 372 μg
Number of subjects: 421

Group type: COMPARATOR
Intervention: Exhalation delivery system–placebo
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: EDS-FLU 186 μg (prior ESS)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: EDS-FLU 372 μg (prior ESS)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Exhalation delivery system–placebo (unoperated)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: EDS-FLU 186 μg (unoperated)
Number of subjects: 421

Group type: EXPERIMENTAL
Intervention: EDS-FLU 372 μg (unoperated)
Number of subjects: 421
Study: 34418958

Group type: EXPERIMENTAL
Intervention: Receiving the results of a SARS-CoV-2 antibody test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: REDCap features for conducting RCT
Number of subjects: 0
Study: 33370007

Group type: EXPERIMENTAL
Intervention: High-dose caffeine (perceived)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low-dose caffeine (perceived)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (perceived)
Number of subjects: 9
Study: 33689730

Group type: EXPERIMENTAL
Intervention: Oxygen therapy at 6 L/min for 6‐12 hours
Number of subjects: 5010

Group type: COMPARATOR
Intervention: Ambient air
Number of subjects: 5010

Group type: EXPERIMENTAL
Intervention: Overall treatment effect
Number of subjects: 5010
Study: 33172445

Group type: EXPERIMENTAL
Intervention: Riboflavin status (normal vs deficient) in relation to MTHFR 677TT genotype
Number of subjects: 6076

Group type: EXPERIMENTAL
Intervention: Deficient riboflavin status with MTHFR 677TT genotype
Number of subjects: 6076

Group type: COMPARATOR
Intervention: Antihypertensive treatment in participants with TT genotype
Number of subjects: 6076
Study: 35467271

Group type: EXPERIMENTAL
Intervention: Low-dose ziprasidone plus sertraline (ZS group)
Number of subjects: 452

Group type: COMPARATOR
Intervention: Usual dose of ziprasidone (control group)
Number of subjects: 452
Study: 33426778

Group type: EXPERIMENTAL
Intervention: Easily digestible meal (starch + sugar-rich meal, SSR)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Slowly digestible meal (protein + fat-rich, PFR)
Number of subjects: 16
Study: 32099328

Group type: EXPERIMENTAL
Intervention: LZM003 (test drug)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Ovidrel® (reference drug)
Number of subjects: 48
Study: 33814237

Group type: EXPERIMENTAL
Intervention: Therapeutic neck dissection (TND)
Number of subjects: 570

Group type: COMPARATOR
Intervention: Elective neck dissection (END)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 570

Group type: EXPERIMENTAL
Intervention: T3 tumors (DOI>10 mm)
Number of subjects: 570
Study: 32151645

Group type: EXPERIMENTAL
Intervention: VIS410
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35985168

Group type: EXPERIMENTAL
Intervention: Eat Breathe Thrive (EBT) program
Number of subjects: 168

Group type: COMPARATOR
Intervention: Waitlist-control condition
Number of subjects: 168
Study: 33831660

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Intensified Prolonged Exposure (iPE)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Skills Training in Affective and Interpersonal Regulation followed by PE (STAIR + PE)
Number of subjects: 149

Group type: COMPARATOR
Intervention: CPTSD
Number of subjects: 149
Study: 33027155

Group type: EXPERIMENTAL
Intervention: Current PrEP use by HIV-negative partners
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Current ART use by HIV-positive partners
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: ART adherence and viral load
Number of subjects: 120
Study: 36273216

Group type: EXPERIMENTAL
Intervention: Phenytoin 20% cream
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Phenytoin 10% cream
Number of subjects: 48

Group type: COMPARATOR
Intervention: Phenytoin 20% cream, Phenytoin 10% cream, Placebo cream
Number of subjects: 48
Study: 34667404

Group type: EXPERIMENTAL
Intervention: Propranolol plus conventional therapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 80
Study: 35659538

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 44

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 44
Study: 32273563

Group type: EXPERIMENTAL
Intervention: Mixed Reality (MR)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Three-Dimensional Visualisation (3DM)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Text-only
Number of subjects: 52
Study: 36191093

Group type: EXPERIMENTAL
Intervention: TOPS device implantation
Number of subjects: 153
Study: 33667417

Group type: EXPERIMENTAL
Intervention: Semaglutide 2·4 mg
Number of subjects: 1210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1210

Group type: EXPERIMENTAL
Intervention: Semaglutide 1·0 mg
Number of subjects: 1210
Study: 33837482

Group type: EXPERIMENTAL
Intervention: Pai‐Neng‐Da Capsule (PNDC) 320 mg/d plus cyclosporine 5 mg/(kg·d) plus andriol 80 mg/d
Number of subjects: 79

Group type: COMPARATOR
Intervention: Cyclosporine 5 mg/(kg·d) plus andriol 160 mg/d
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: PCA group
Number of subjects: 79
Study: 33139710

Group type: EXPERIMENTAL
Intervention: Nimodipine (60 mg single oral dose)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 33734725

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Expecting Adderall
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65

Group type: COMPARATOR
Intervention: Expecting caffeine
Number of subjects: 65
Study: 34341037

Group type: EXPERIMENTAL
Intervention: 5% lidocaine-medicated plaster (LMP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study: 32111343

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg of psilocybin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 35902234

Group type: EXPERIMENTAL
Intervention: IVT+MT
Number of subjects: 408

Group type: COMPARATOR
Intervention: MT alone
Number of subjects: 408
Study: 34128894

Group type: EXPERIMENTAL
Intervention: Body and breath regulation group (n=72)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Body regulation group (n=72)
Number of subjects: 144
Study: 32826295

Group type: EXPERIMENTAL
Intervention: Higher plasma kallikrein levels (measured in nmol/L) during DCCT/EDIC
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Higher plasma kallikrein levels during EDIC only
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Higher plasma kallikrein levels during EDIC follow-up, adjusted for age and mean HbA1c
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Higher plasma kallikrein levels during EDIC follow-up, fully adjusted for other CVD risk factors
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Higher plasma kallikrein levels during EDIC only, minimally adjusted
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Higher plasma kallikrein levels during EDIC only, fully adjusted
Number of subjects: 693